Country: United Kingdom
Language: English
Source: VMD (Veterinary Medicines Directorate)
Thiamazole
Norbrook Laboratories Limited
QH03BB02
Thiamazole
Oral solution
POM-V - Prescription Only Medicine – Veterinarian
Cats
Anti Hormone Agent
Authorized
2016-05-19
Revised: July 2021 AN: 01048/2020 Page 1 of 7 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Normazole 5 mg/ml Oral Solution for Cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: ACTIVE SUBSTANCE: Thiamazole 5 mg EXCIPIENT: Sodium Benzoate (E211) 1.5 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Oral solution An off-white to light yellow opaque solution 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cats 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the stabilisation of hyperthyroidism in cats prior to surgical thyroidectomy. For the long term treatment of feline hyperthyroidism. 4.3 CONTRAINDICATIONS Do not use in cats suffering from systemic disease such as primary liver disease or diabetes mellitus. Do not use in cats showing signs of autoimmune disease. Do not use in animals with disorders of white blood cells, such as neutropenia and lymphopenia. Do not use in animals with platelet disorders and coagulopathies (particularly thrombocytopenia). Do not use in pregnant or lactating females. Please refer to section 4.7. Do not use in known cases of hypersensitivity to the active substance or to any of the excipients. Revised: July 2021 AN: 01048/2020 Page 2 of 7 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES In order to enhance stabilisation of the hyperthyroid patient the same feeding and dosing schedule should be used daily. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals If more than 10 mg of thiamazole per day is required animals should be monitored particularly carefully. Use of the product in cats with renal dysfunction should be subject to careful risk:benefit assessment by the clinician. Due to the effect thiamazole can have on reducing the glomerular filtration rate, the effect of therapy on renal function should be monitored closely as deterioration of an underlying renal impairment may occur. Haematology must be monitored due to risk of leucopenia or haemolytic anaemia before initiating treatmen Read the complete document